Loading...
Loading...
GNLX| Name | Value |
|---|---|
| Revenues | 896.0K |
| Cost of Revenue | 452.0K |
| Gross Profit | -227.0K |
| Operating Expense | 9,521.0K |
| Operating I/L | -9,748.0K |
| Other Income/Expense | 772.0K |
| Interest Income | 402.0K |
| Pretax | -8,976.0K |
| Income Tax Expense | 0.0K |
| Net Income/Loss | -8,976.0K |
Genelux Corporation is a clinical-stage biopharmaceutical company specializing in the development of oncolytic viral immunotherapies for aggressive solid tumors. Its lead product candidate, Olvi-Vec, is a modified strain of the vaccinia virus designed for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also working on V2ACT Immunotherapy for pancreatic cancer and V-VET1 for hematologic and solid cancer.
